Skip to main content
Premium Trial:

Request an Annual Quote

Seems Effective in Kids

US Food and Drug Administration officials say the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease, the Associated Press reports.

Pfizer and BioNTech, it adds, had reported that their vaccine was 91 percent effective at preventing symptomatic infections in children between 5 years and 11 years old, noting that the FDA analysis supports the finding. The Pfizer-BioNTech vaccine is already authorized for adolescents between the ages of 12 and 15 years old and approved for people 16 years old and older. CNN adds that the Pfizer-BioNTech SARS-CoV-2 vaccine for children is a 10-microgram dose, as compared to the 30-microgram dose given to adolescents and adults, though it is still administered in a two-dose regimen.

The AP adds that an independent FDA panel is to review the data on Tuesday, with an FDA decision coming after that. If it authorizes the vaccine, then the Centers for Disease Control and Preventing will weigh in on who should be eligible for vaccination, it notes, adding that kids could begin to receive vaccinations as early as the first week of November.

Moderna, the New York Times reports, has additionally announced that its SAR-CoV-2 vaccine, also given at a lower dose at two time points, appears to generate an immune response among children aged 6 to 11 years.

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.